Skip to content

Role of Aging and Individual Variation in Exercise Training Responsiveness

The Role of Aging and Individual Variation in Exercise Training Responsiveness

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06471569
Acronym
STRRIDE IV
Enrollment
9
Registered
2024-06-24
Start date
2025-04-02
Completion date
2026-05-29
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Insulin Resistance, Obesity, Prediabetic State

Keywords

Exercise, Cardiorespiratory Fitness, Functional Capacity, Cardiometabolic Risk, Physical Reserve, Physical Resilience

Brief summary

The primary purpose of this study is to assess the effects of aging on markers of physical reserve and exercise-induced adaptations in resilience in older adults who completed a structured exercise program within the last 15 years (Parent trial: STRRIDE-PD; NCT00962962). This feasibility pilot study will enroll up to 26 participants to complete a 6-month aerobic exercise intervention.

Interventions

BEHAVIORALLow/Mod

Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial

BEHAVIORALHigh/Mod

Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial

BEHAVIORALHigh/Vig

Aerobic exercise at 75% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial

Sponsors

Duke University
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Individuals who completed participation in the STRRIDE-PD trial (NCT00962962) * Body Mass Index (BMI) \> 18 and \< 45 kg/m2 * Stable dose (≥1 month) of any cardiometabolic medications

Exclusion criteria

* Poor vein access * Current use of tobacco or any nicotine products, including e-cigarettes * Insulin-dependent diabetes * Active untreated hypothyroidism with thyroid stimulating hormone (TSH) concentrations \> 10.0 uIU/mL * Systemic inflammatory or connective tissue disease, chronic infectious disease, chronic pulmonary disease or symptomatic cardiovascular disease with positive functional study by ECG or imaging * Current, actively treated malignancy other than dermatologic conditions * Absolute contraindications to exercise testing: ongoing unstable angina; uncontrolled cardiac arrhythmia with hemodynamic compromise; active endocarditis; symptomatic severe aortic stenosis; decompensated heart failure; acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis; acute myocarditis or pericarditis; acute aortic dissection; physical disability that precludes safe and adequate testing * Relative contraindications to exercise testing: known obstructive left main coronary artery stenosis; moderate to severe aortic stenosis with uncertain relation to symptoms; tachyarrhythmias with uncontrolled ventricular rates; acquired advanced or complete heart block; hypertrophic obstructive cardiomyopathy with severe resting gradient; recent stroke or transient ischemic attack; mental impairment with limited ability to cooperate; uncorrected medical conditions, such as hypertension, significant anemia, important electrolyte imbalance, and hyperthyroidism * Modified testing contraindications: acute myocardial infarction (MI) within six months; resting hypertension with systolic or diastolic blood pressures \>160/90 mmHg * Unable to safely participate in an exercise program per study protocol per PI discretion * Planned, intentional weight loss during study

Design outcomes

Primary

MeasureTime frameDescription
Insulin SensitivityBaseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)Insulin sensitivity will be measured with a 2-hour oral glucose tolerance test
Cardiorespiratory FitnessBaseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)Cardiorespiratory fitness will be measured with a maximal cardiopulmonary exercise test

Secondary

MeasureTime frameDescription
Perceived Global HealthBaseline, early-intervention (~6 weeks), mid-intervention (~12 weeks), and post-intervention (~24 weeks)Self-reported global health will be captured using the Patient-Reported Outcomes Measurement Information System (PROMIS). The questionnaire will be scored using "response pattern scoring" according to the PROMIS scoring manual in order to calculate the T-score for this outcome measure. The population mean T-score for global health is 50, with a score of 40 considered below average and a score of 60 considered above average.
Health-Related Quality of LifeBaseline, early-intervention (~6 weeks), mid-intervention (~12 weeks), and post-intervention (~24 weeks)Health-related quality of life will be captured using the SF-36 Health Survey. The survey is scored into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Raw scores will be converted into scale scores ranging from 0 to 100, with higher scores representing better health-related quality of life.
Metabolic Syndrome Z-ScoreBaseline, early-intervention (~6 weeks), mid-intervention (~12 weeks), and post-intervention (~24 weeks)The metabolic syndrome z-score (MSSc) is a continuous weighted score of the five metabolic syndrome variables-fasting high-density lipoprotein cholesterol, triglycerides, glucose, waist circumference, and mean arterial blood pressure. A modified z-score will be calculated for each participant using continuous differences between the Adult Treatment Panel (ATP) III guideline values and participant values with normalization to the cohort's standard deviations. To account for variations in ATP III criteria between men and women, the investigators will use sex-specific MSSc equations. A lower MSSc indicates a better outcome.
Body CompositionBaseline and post-intervention (~24 weeks)Body composition will be assessed as percent fat mass and percent fat-free mass.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLeanna M Ross, PhD

Duke University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026